Prexasertib mesylate monohydrate is under clinical development by Acrivon Therapeutics and currently in the Phase I and Phase II in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.
According to GlobalData, the latest event to affect Prexasertib mesylate monohydrate’s likelihood of approval (LoA) and phase transition for Fallopian Tube Cancer took place on 17 Oct 2022, which decreased the likelihood that the drug progresses to the next phase in its clinical pathway and decreased the likelihood of final approval for this indication.
In addition, the same event on 17 Oct 2022 decreased Prexasertib mesylate monohydrate’s LoA and PTSR for Peritoneal Cancer.
GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their Prexasertib mesylate monohydrate Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.
Prexasertib mesylate monohydrate overview
Prexasertib (LY-2606368 monomesylate monohydrate) is under development for the treatment of pediatric CNS tumors including refractory or recurrent medulloblastoma, metastatic ovarian cancer, endometrial cancer, metastatic and unresectable urothelial carcinoma, peritoneal cancer, fallopian tube cancer, bladder cancer, cervical cancer, squamous cell carcinoma of head and neck cancer and squamous cell cancer of the anus. It was also under development for metastatic colorectal cancer, squamous cell carcinomas including squamous non-small cell lung cancer, epithelial ovarian cancer, peritoneal cancer, fallopian tube cancer, extensive stage disease small-cell lung cancer, metastatic castrate-resistant prostate cancer, metastatic triple negative breast cancer, relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndrome and pediatric CNS tumors including neuroblastoma, childhood rhabdomyosarcoma. The drug candidate is administered intravenously. It is a new chemical entity (NCE) which acts by targeting Chk1 and Chk2 protein kinase.
Acrivon Therapeutics overview
Acrivon Therapeutics (Acrivon) is a biotechnology company that specializing in drug development through early clinical treatment success. Acrivon is headquartered in Watertown, Massachusetts, the US.
Quick View Prexasertib mesylate monohydrate LOA Data
|Highest Development Stage|